Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320697 · ClinicalTrials.gov registry record · Phase 4
Smoking Relapse Prevention in Schizophrenia
A Phase 4 study, sponsored by North Suffolk Mental Health Association.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00320697 is a Phase 4 study that has completed, run by North Suffolk Mental Health Association. The registered enrollment target is 25 participants.
The verdict
NCT00320697, a Phase 4 study, has completed, sponsored by North Suffolk Mental Health Association.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
Interventions
- DRUG bupropion + nicotine patch + nicotine gum or lozenges
- DRUG Placebo pill + placebo patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320697
The ClinicalTrials.gov registry entry for NCT00320697 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Suffolk Mental Health Association, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bupropion + nicotine patch + nicotine gum or lozenges is the first listed.
NCT00320697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320697 about?
NCT00320697 is a clinical study titled "Smoking Relapse Prevention in Schizophrenia". This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
What is the current status of trial NCT00320697?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2006-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00320697?
The interventions under investigation include: bupropion + nicotine patch + nicotine gum or lozenges (DRUG), Placebo pill + placebo patch (DRUG).
Who is sponsoring clinical trial NCT00320697?
This trial is sponsored by North Suffolk Mental Health Association, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.